Compare Toronto-Dominion Bank (TD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs State Street SPDR S&P Biotech ETF — how do they compare? Toronto-Dominion Bank trades at $115.1 (market cap $185.79B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Toronto-Dominion Bank is far larger — about 18.4× State Street SPDR S&P Biotech ETF's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 84 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TD | XBI | |
|---|---|---|
Market Cap | $185.79B | $10.11B |
Volume | 3,263,867 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $124.80 | $169.55 |
52-Week Low | $78.32 | $104.99 |
Typical Hold Time | 84 Days | 38 Days |
Enterprise Value | $559.06B | — |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $115.10, up 1.08% with a bearish technical signal despite strong earnings beats in recent quarters. The company maintains solid profitability with 24.88% net income margin and 13.64% ROE, supported by a $10 billion share buyback announcement. Recent news highlights expansion plans including 100 new U.S. branches and a $108 billion commitment to Canadian infrastructure.
The outlook remains positive with analyst consensus favoring Buy ratings (52.94%) and consistent earnings outperformance, though technical indicators suggest near-term pressure. Key risks include volatile cash flows and rising debt-to-asset ratios, while institutional activity shows mixed sentiment with recent insider selling.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
